MIRA INFORM REPORT
|
Report Date : |
09.06.2014 |
IDENTIFICATION DETAILS
|
Name : |
GVK BIOSCIENCES PRIVATE LIMITED |
|
|
|
|
Registered
Office : |
Plot No.28 A, IDA Nacharam, Hyderabad-500 076, Andhra Pradesh |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as
on) : |
31.03.2013 |
|
|
|
|
Date of
Incorporation : |
01-035826 |
|
|
|
|
Com. Reg. No.: |
07.12.2000 |
|
|
|
|
Capital
Investment / Paid-up Capital : |
Rs.165.450
Millions |
|
|
|
|
CIN No.: [Company Identification
No.] |
U74999TG2000PTC035826 |
|
|
|
|
TAN No.: [Tax Deduction &
Collection Account No.] |
HYDG00774E |
|
|
|
|
PAN No.: [Permanent Account No.] |
AABCG3208J |
|
|
|
|
Legal Form : |
Private Limited Liability Company |
|
|
|
|
Line of Business
: |
Provides drug discovery and development services to pharmaceutical
companies. |
|
|
|
|
No. of Employees
: |
Information declined by the management |
RATING & COMMENTS
|
MIRA’s Rating : |
A (65) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
Maximum Credit Limit : |
USD 15000000 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Exist |
|
|
|
|
Comments : |
Subject is a well-established company having fine track record. The company possesses a strong financial profile marked by healthy capital
structure and liquidity position. Management has reported a decent sales volume as well as net
profitability along with healthy profitability margin during FY13. Trade relations are trustworthy. Business is active. Payment terms are
reported as regular and as per commitments. In view of established track record and its strong clientele, the
subject can be considered for business dealings at usual trade terms and
conditions. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2014
|
Country Name |
Previous Rating (31.12.2013) |
Current Rating (31.03.2014) |
|
India |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
INDIAN ECONOMIC OVERVIEW
US investment bank
Goldman Sachs has upgraded its outlook on Indian markets as it expects
positive impact of the election cycle.
India’s economy may
grow 4.7 % in the current financial year, lower than the official estimate of
4.9 %, Fitch Rating said. The global rating agency expects the economy to pick
up in the next two financial years.
Global ratings
agency Standard & Poor said increasing focus by India Inc on lowering debt
is likely to improve their credit profiles.
Singapore (1.1 million
Indian tourists in 2012), Thailand (one million), the United Arab Emirates
().98 million) and Malaysia ().82 million) emerged as the preferred holidays
hotspots for Indians. The total figure is expected to increase to 1.93 million
by 2017, according to the latest Eurmonitor international report.
There is a $29.34 bn
outward foreign direct investment by domestic companies between April and
January of 2013/14 which has seen some signs of recovery according to a Care
Ratings report.
There are 264 number
of new companies being set up every day on average during 2014. Most of them
are registered in Mumbai. India had 1.38 million registered companies at the
end of January, 2014.
Twitter like
messaging service Weibo Corporation has filed to raise $ 500 million via a US
initial public offering. Alibaba, which owns a stake in Weibo is expected to
raise about $ 15 billion New York this year in the highest profile Internet IPO
since Facebook’s in 2012.
Bharti Airtel has
raised Rs.2,453.2 crore (350 million Swiss Francs) by selling six-year bonds at
a coupon rate of three per cent and maturing in 2020. This is the largest ever
bond offering by an Indian company in Swiss Francs. Bharat Petroleum
Corporation raised 175 million Swiss Francs by selling five year bonds at 2.98
% coupon rate in February.
Indian Oil
Corporation plans to invest Rs 7650 crore in setting up a petrochemical complex
at its almost complete Paradip refinery in Odhisha in three to four years. The
company board is set to consider the setting up of a 700000 tonne per annum
polypropylene plant at an estimated cost at Rs.3150 crore.
Global chief
information officers at gathering in Bangalore in April to meet Indian startups
at an event called Tech50 Watchout for Little Eye Labs-Facebook type deals in
the making.
EXTERNAL AGENCY RATING
|
Rating Agency Name |
CRISIL |
|
Rating |
Long Term Rating = A+ |
|
Rating Explanation |
Adequate degree of safety and low credit risk |
|
Date |
27.09.2013 |
|
Rating Agency Name |
CRISIL |
|
Rating |
Short Term Rating = A1+ |
|
Rating Explanation |
Very strong degree of safety and lowest credit risk. |
|
Date |
27.09.2013 |
RBI DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available RBI Defaulters’ list.
EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of
31-03-2012.
INFORMATION DECLINED
Management Non Co-operative (91-40-66929999)
LOCATIONS
|
Registered Office / Corporate Office : |
Plot No.28 A, IDA Nacharam, Hyderabad-500 076, |
|
Tel. No.: |
91-40-66929999 |
|
Fax No.: |
91-40-66929900 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Administrative
Offices : |
7th Floor, Swarna Jayanthi Commercial Complex, Ameerpeet, |
|
Tel No: |
91-40-66628888 / 66635555 |
|
|
|
|
Overseas Offices: |
Located
At:
|
DIRECTORS
As on 22.05.2013
|
Name : |
Mr. Davinder Singh Brar |
|
Designation : |
Chairman |
|
Address : |
Greenfields Farm, Gadalpur- Jaunapur road, Village, Jaunapur, Tehsil-
Mehrauli, New Delhi-110 030, Delhi, India |
|
Date of Birth : |
21.08.1952 |
|
Date of Appointment : |
26.07.2004 |
|
DIN No.: |
00068502 |
|
PAN No.: |
AAGPB0665A |
|
|
|
|
Name : |
Mr. Gunapati Venkata Sanjay Reddy |
|
Designation : |
Director |
|
Address : |
H No.6-3-1089/A/5, |
|
Date of Birth : |
18.11.1964 |
|
Date of Appointment : |
07.12.2000 |
|
DIN No.: |
00005282 |
|
|
|
|
Name : |
Mr. Gunapati Indira Krishna Reddy |
|
Designation : |
Director |
|
Address : |
H No.6-3-250, Road No.1, Banjara Hills, Hyderabad-500034, |
|
Date of Birth : |
17.10.1944 |
|
Date of Appointment : |
07.06.2002 |
|
DIN No.: |
00005230 |
|
|
|
|
Name : |
Professor Tarun Khanna |
|
Designation : |
Director |
|
Address : |
66, Druid Hill Road, Newton-02461, |
|
Date of Birth : |
09.05.1966 |
|
Date of Appointment : |
19.06.2009 |
|
DIN No.: |
01760700 |
|
|
|
|
Name : |
Mr. Gerhard Mayr |
|
Designation : |
Director |
|
Address : |
5, Eaton Square, London SW1W9AQ, UK |
|
Date of Birth : |
05.12.1946 |
|
Date of Appointment : |
21.07.2009 |
|
DIN No.: |
02734832 |
|
|
|
|
Name : |
Mr. Krishna Ram Bhupal |
|
Designation : |
Director |
|
Address : |
House No.6-3-250/1, Road No.1, Banjara Hills, Hyderabad-400 018, |
|
Date of Birth : |
16.03.1983 |
|
Date of Appointment : |
20.10.2009 |
|
DIN No.: |
00005442 |
|
|
|
|
Name : |
Mr. Ahay Kumar Pandey |
|
Designation : |
Alternate Director to Sandeep Singhal |
|
Address : |
1402 Purna, |
|
Date of Birth : |
01.12.1971 |
|
Date of Appointment : |
21.07.2009 |
|
DIN No.: |
01650845 |
KEY EXECUTIVES
|
Name : |
Mr. K. Ramkrishna |
|
Designation : |
Company Secretary |
|
Address : |
505, Saipriya Apartments, LIC Colony, Gudimalkapur, Hyderabad-500 028,
|
|
Date of Birth : |
09.03.1968 |
|
Date of Appointment : |
06.12.2007 |
|
PAN No.: |
ADFPK5005M |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
As on 22.05.2013
|
Names of Shareholders |
|
No. of Shares |
|
G. V. Sanjay Reddy |
|
978750 |
|
G. V. Krishna Reddy |
|
407814 |
|
G. Indira K Reddy |
|
407811 |
|
Shalini Bhupal |
|
407811 |
|
G. Aparna Reddy |
|
652500 |
|
GVK Davix Technologies Private Limited, |
|
8475000 |
|
Devinder singh Brar |
|
3262500 |
|
Sequoia Capital |
|
1545000 |
|
Shriya Bhupal |
|
203907 |
|
|
|
203907 |
|
Total |
|
16545000 |
As on 22.05.2013
Equity Share Break up (Percentage of Total Equity)
|
Category |
Percentage |
|
Foreign holdings( Foreign institutional investor(s),
Foreign companie(s) Foreign financial institution(s), Non-resident Indian(s)
or Overseas Corporate bodies or Others |
9.34 |
|
Bodies corporate |
51.22 |
|
Directors or relatives of Directors |
39.44 |
|
Total |
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Provides drug discovery and development services to pharmaceutical
companies. |
GENERAL INFORMATION
|
No. of Employees : |
Information declined by the management |
|||||||||||||||
|
|
|
|||||||||||||||
|
Bankers : |
|
|||||||||||||||
|
|
|
|||||||||||||||
|
Facilities : |
(Rs.
In Millions)
|
|
|
|
|
Banking
Relations : |
--- |
|
|
|
|
Auditors : |
|
|
Name : |
Walker, Chandiok and Company Chartered Accountants |
|
Address : |
7rd Floor, Uptown Banjara, Road No. 3, Banjara Hills, Hyderabad
- 500034, Andhra Pradesh, India |
|
Tel. No.: |
91-40-64528666 |
|
Fax No.: |
91-40-23540224 |
|
E-Mail : |
|
|
PAN No.: |
AAAFW4298E |
|
|
|
|
Ultimate Holding
Company : |
G.V. Sanjay Reddy |
|
|
|
|
Holding Company |
GVK Davix Technologies Private Limited |
|
|
|
|
Subsidiary |
GVK Biosciences Private Limited |
|
|
|
|
Joint venture(upto
21 December 2011) |
INC GVKBIO Private Limited |
|
|
|
|
Significant influence
of key management personel |
|
|
|
|
|
Associate : |
Inogent Laboratories Private Limited |
|
|
|
|
Fellow Subsidiary: |
GVK Biosciences Inc. |
CAPITAL STRUCTURE
As on 22.05.2013
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
20000000 |
Equity Shares |
Rs.10/- each |
Rs.200.000 Millions |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
16545000 |
Equity Shares |
Rs.10/- each |
Rs.165.450
Millions |
|
|
|
|
|
FINANCIAL DATA
[all figures are in
Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
|
31.03.2013 |
31.03.2012 |
|
I.
EQUITY
AND LIABILITIES |
|
|
|
|
(1)Shareholders' Funds |
|
|
|
|
(a) Share Capital |
|
165.450 |
165.450 |
|
(b) Reserves & Surplus |
|
3659.504 |
3096.109 |
|
(c) Money
received against share warrants |
|
0.000 |
0.000 |
|
|
|
|
|
|
(2) Share Application money pending
allotment |
|
0.000 |
0.000 |
|
Total
Shareholders’ Funds (1) + (2) |
|
3824.954 |
3261.559 |
|
|
|
|
|
|
(3)
Non-Current Liabilities |
|
|
|
|
(a) long-term borrowings |
|
0.000 |
0.000 |
|
(b) Deferred tax liabilities (Net) |
|
0.000 |
0.000 |
|
(c) Other long term
liabilities |
|
0.000 |
0.000 |
|
(d) long-term
provisions |
|
11.677 |
10.957 |
|
Total Non-current
Liabilities (3) |
|
11.677 |
10.957 |
|
|
|
|
|
|
(4)
Current Liabilities |
|
|
|
|
(a) Short
term borrowings |
|
344.801 |
258.680 |
|
(b) Trade
payables |
|
328.979 |
336.790 |
|
(c) Other
current liabilities |
|
118.628 |
100.966 |
|
(d) Short-term
provisions |
|
78.480 |
55.617 |
|
Total Current
Liabilities (4) |
|
870.888 |
752.053 |
|
|
|
|
|
|
TOTAL |
|
4707.519 |
4024.569 |
|
|
|
|
|
|
II.
ASSETS |
|
|
|
|
(1)
Non-current assets |
|
|
|
|
(a) Fixed Assets |
|
|
|
|
(i)
Tangible assets |
|
942.285 |
1075.154 |
|
(ii)
Intangible Assets |
|
1.841 |
6.016 |
|
(iii)
Capital work-in-progress |
|
250.275 |
220.543 |
|
(iv)
Intangible assets under development |
|
0.000 |
0.000 |
|
(b) Non-current Investments |
|
295.107 |
265.107 |
|
(c) Deferred tax assets (net) |
|
83.049 |
42.805 |
|
(d) Long-term Loan and Advances |
|
845.765 |
707.326 |
|
(e) Other
Non-current assets |
|
0.000 |
0.000 |
|
Total Non-Current
Assets |
|
2418.322 |
2316.951 |
|
|
|
|
|
|
(2)
Current assets |
|
|
|
|
(a)
Current investments |
|
0.000 |
0.000 |
|
(b)
Inventories |
|
20.418 |
26.407 |
|
(c) Trade
receivables |
|
616.131 |
488.277 |
|
(d) Cash
and cash equivalents |
|
1163.363 |
738.509 |
|
(e)
Short-term loans and advances |
|
367.447 |
365.353 |
|
(f) Other
current assets |
|
121.838 |
89.072 |
|
Total
Current Assets |
|
2289.197 |
1707.618 |
|
|
|
|
|
|
TOTAL |
|
4707.519 |
4024.569 |
|
SOURCES OF FUNDS |
|
|
31.03.2011 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
|
|
165.450 |
|
|
2] Share Application Money |
|
|
0.000 |
|
|
3] Reserves & Surplus |
|
|
2471.465 |
|
|
4] (Accumulated Losses) |
|
|
0.000 |
|
|
NETWORTH |
|
|
2636.915 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
|
|
388.584 |
|
|
2] Unsecured Loans |
|
|
0.000 |
|
|
TOTAL BORROWING |
|
|
388.584 |
|
|
DEFERRED TAX LIABILITIES |
|
|
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
|
|
3025.499 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
|
|
1308.307 |
|
|
Capital work-in-progress |
|
|
302.611 |
|
|
|
|
|
|
|
|
INVESTMENT |
|
|
206.985 |
|
|
DEFERREX TAX ASSETS |
|
|
11.305 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
|
|
22.160
|
|
|
Sundry Debtors |
|
|
474.021
|
|
|
Cash & Bank Balances |
|
|
382.086
|
|
|
Other Current Assets |
|
|
9.743
|
|
|
Loans & Advances |
|
|
658.132
|
|
Total
Current Assets |
|
|
1546.142
|
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Sundry Creditors |
|
|
226.311
|
|
|
Other Current Liabilities |
|
|
71.856
|
|
|
Provisions |
|
|
51.684
|
|
Total
Current Liabilities |
|
|
349.851
|
|
|
Net Current Assets |
|
|
1196.291
|
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
|
|
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
|
|
3025.499 |
|
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.03.2013 |
31.03.2012 |
31.03.2011 |
|
|
|
SALES |
|
|
|
|
|
|
|
|
3137.431 |
3061.665 |
|
|
|
|
Other Income |
|
|
|
|
|
|
TOTAL (A) |
3137.431 |
3061.665 |
2556.641 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
Office Expenses |
|
|
|
|
|
|
Administrative Expenses |
2259.453 |
2251.824 |
1971.448 |
|
|
|
Advertising Expenses |
|
|
|
|
|
|
TOTAL (B) |
2259.453 |
2251.824 |
1971.448 |
|
|
|
|
|
|
|
|
Less |
PROFIT
BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B) (C) |
877.978 |
809.841 |
585.193 |
|
|
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES (D) |
11.304 |
13.014 |
26.237 |
|
|
|
|
|
|
|
|
|
|
PROFIT
BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D) (E) |
866.674 |
796.827 |
558.956 |
|
|
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION (F) |
243.453 |
304.228 |
272.154 |
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX (E-F) (G) |
623.221 |
492.599 |
286.802 |
|
|
|
|
|
|
|
|
|
Less |
TAX (H) |
16.530 |
(160.889) |
3.148 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAX
(G-H) (I) |
606.691 |
653.488 |
283.654 |
|
|
|
|
|
|
|
|
|
Add |
PREVIOUS
YEARS’ BALANCE BROUGHT FORWARD |
2060.782 |
1468.812 |
1215.324 |
|
|
|
|
|
|
|
|
|
Less |
APPROPRIATIONS |
|
|
|
|
|
|
|
Transfer to General Reserve |
60.669 |
32.674 |
7.091 |
|
|
|
Tax on Dividend |
48.072 |
28.844 |
23.075 |
|
|
BALANCE CARRIED
TO THE B/S |
2558.732 |
2060.782 |
1468.812 |
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.) |
36.67 |
39.50 |
17.14 |
|
KEY RATIOS
|
PARTICULARS |
|
31.03.2013 |
31.03.2012 |
31.03.2011 |
|
PAT / Total Income |
(%) |
19.34 |
21.34 |
11.09 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
15.28 |
14.09 |
10.05
|
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.16 |
0.15 |
0.11
|
|
|
|
|
|
|
|
Debt Equity Ratio (Total Debt /Networth) |
|
0.09 |
0.08 |
0.15
|
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
2.63 |
2.27 |
4.42
|
FINANCIAL ANALYSIS
[all figures are
in Rupees Millions]
DEBT EQUITY RATIO
|
Particular |
|
31.03.2012 |
31.03.2013 |
|
|
|
(Rs.
In Millions) |
(Rs.
In Millions) |
|
Share Capital |
|
165.450 |
165.450 |
|
Reserves & Surplus |
|
3096.109 |
3659.504 |
|
Net
worth |
|
3261.559 |
3824.954 |
|
|
|
|
|
|
long-term borrowings |
|
0.000 |
0.000 |
|
Short term borrowings |
|
258.680 |
344.801 |
|
Total
borrowings |
|
258.680 |
344.801 |
|
Debt/Equity
ratio |
|
0.079 |
0.090 |
YEAR-ON-YEAR GROWTH
|
Year
on Year Growth |
31.03.2011 |
31.03.2012 |
31.03.2013 |
|
|
(Rs.
In Millions) |
(Rs.
In Millions) |
(Rs.
In Millions) |
|
Sales |
2556.641 |
3061.665 |
3137.431 |
|
|
|
19.753 |
2.475 |
NET PROFIT MARGIN
|
Net
Profit Margin |
31.03.2011 |
31.03.2012 |
31.03.2013 |
|
|
(Rs.
In Millions) |
(Rs.
In Millions) |
(Rs.
In Millions) |
|
Sales |
2556.641 |
3061.665 |
3137.431 |
|
Profit |
283.654 |
653.488 |
606.691 |
|
|
11.09% |
21.34% |
19.34% |
LOCAL AGENCY FURTHER INFORMATION
|
Sr. No. |
Check List by Info
Agents |
Available in Report (Yes / No) |
|
1] |
Year of Establishment |
Yes |
|
2] |
Locality of the firm |
Yes |
|
3] |
Constitutions of the firm |
Yes |
|
4] |
Premises details |
No |
|
5] |
Type of Business |
Yes |
|
6] |
Line of Business |
Yes |
|
7] |
Promoter's background |
Yes |
|
8] |
No. of employees |
No |
|
9] |
Name of person contacted |
No |
|
10] |
Designation of contact person |
No |
|
11] |
Turnover of firm for last three years |
Yes |
|
12] |
Profitability for last three years |
Yes |
|
13] |
Reasons for variation <> 20% |
---------------------- |
|
14] |
Estimation for coming financial year |
No |
|
15] |
Capital in the business |
Yes |
|
16] |
Details of sister concerns |
Yes |
|
17] |
Major suppliers |
No |
|
18] |
Major customers |
No |
|
19] |
Payments terms |
No |
|
20] |
Export / Import details (if applicable) |
No |
|
21] |
Market information |
---------------------- |
|
22] |
Litigations that the firm / promoter involved in |
Yes |
|
23] |
Banking Details |
Yes |
|
24] |
Banking facility details |
Yes |
|
25] |
Conduct of the banking account |
---------------------- |
|
26] |
Buyer visit details |
---------------------- |
|
27] |
Financials, if provided |
Yes |
|
28] |
Incorporation details, if applicable |
Yes |
|
29] |
Last accounts filed at ROC |
Yes |
|
30] |
Major Shareholders, if available |
Yes |
|
31] |
Date of Birth of Proprietor/Partner/Director, if available |
Yes |
|
32] |
PAN of Proprietor/Partner/Director, if available |
Yes |
|
33] |
Voter ID No of Proprietor/Partner/Director, if available |
No |
|
34] |
External Agency Rating, if available |
Yes |
Note:
The registered office of the company has been shifted from
#210, My Home Tycoon 6-3-1192, Kundanbagh, Begumpet, Hyderabad, Andhra Pradesh,
India to
present address w.e.f. 04.11.2009
LITIGATIONS DETAILS
|
CP 176 / 2012 |
CPSR 5042 / 2012 |
CASE IS:PENDING |
|
PETITIONER |
RESPONDENT |
|
|
SYSTIME GLOBAL SOLUTION PRIVATE LIMITED |
VS |
M/S.GVK BIOSCIENCES PRIVATE LIMITED |
|
PET.ADV. : DESHPANDE |
RESP.ADV. : RAJU |
|
|
SUBJECT: COMPANY PETITION |
DISTRICT: HYDERABAD |
|
FILING DATE: 24-08-2012 |
POSTING STAGE : FOR ADMISSION |
|
|
REG. DATE : 26-09-2012 |
LISTING DATE : 15-02-2014 |
STATUS : --------- |
|
HON'BLE JUDGE(S): |
RAMESH RANGANATHAN |
INDEX OF CHARGES
|
S.No. |
Charge ID |
Date of Charge
Creation/Modification |
Charge amount
secured |
Charge Holder |
Address |
Service Request
Number (SRN) |
|
1 |
10478342 |
29/01/2014 |
400,000,000.00 |
KOTAK MAHINDRA BANK LIMITED |
36-38A, NARIMAN BHAVAN, 227,D, NARIMAN POINT,, MUMBAI, MAHARASHTRA - 400021, INDIA |
B96699640 |
|
2 |
10118828 |
20/03/2009 * |
118,000,000.00 |
CITIBANK N.A |
1ST FLOOR, QUEENS PLAZA, S.P. ROAD, BEGUMPET, HYDERABAD, ANDHRA PRADESH - 500003, INDIA |
A59931733 |
|
3 |
10072893 |
31/03/2007 |
75,000,000.00 |
YES BANK LIMITED |
9TH FLOOR, NEHRU CENTRE, DISCOVERY OF INDIA,
DR. ANNIE BESANT ROAD, WORLI, MUMBAI, MAHARASHTRA - |
A25366196 |
|
4 |
10013686 |
16/12/2013 * |
390,000,000.00 |
KOTAK MAHINDRA BANK LIMITED |
36-38A, NARIMAN BHAVAN, 227,D, NARIMAN POINT, MUMBAI, MAHARASHTRA - 400021, INDIA |
B94257144 |
|
5 |
10103106 |
20/07/2013 * |
375,000,000.00 |
YES BANK LIMITED |
YES BANK LIMITED, 9TH FLOOR, NEHRU CENTRE, DISCOVERY OF INDIA,, MUMBAI, MAHARASHTRA - 400018, INDIA |
B82077157 |
|
6 |
90124475 |
31/10/2013 * |
177,000,000.00 |
CANARA BANK |
PRIME CORPORATE BRANCH, 1-7-1, TSR COMPLEX, SP ROAD, SECUNDERABAD, ANDHRA PRADESH - 500003, INDIA |
B89549356 |
|
7 |
90124333 |
15/07/2005 * |
205,800,000.00 |
CANARA KBANK |
INDUSTRIAL FINANCE BRANCH S.P. ROAD, SECUNDERABAD, ANDHRA PRADESH - 500003, INDIA |
- |
|
8 |
90124315 |
06/11/2003 * |
16,500,000.00 |
INDIAN OVERSEAS BANK |
M.G. ROAD BRANCH, CHANDRALOK COMLEX, SECUNDERABAD, ANDHRA PRADESH - 500003, INDIA |
- |
|
9 |
90124232 |
23/02/2001 |
20,000,000.00 |
ICICI BANK LIMITED |
TGV MANSIONS; 6-2-1012 KHAIRATABAD, HYDERABAD, ANDHRA PRADESH - 500004, INDIA |
- |
* Date of charge modification
FIXED ASSETS
- Land
- Buildings
- Furniture and fixtures
- Vehicles
- Office equipment
- Computer equipments
AS PER WEBSITE
PRESS RELEASE
GVK BIOSCIENCES TO
SET UP NEW RESEARCH LAB IN VIZAG
March 22, 2014
GVK Biosciences Private Limited, a Hyderabad-based contract research organization (CRO), on Friday said it plans to invest around Rs.1000.000 Millions to set up a new facility in the coastal city of Vizag as part of its expansion plans.
The new facility will house chemistry and biology laboratories of 200,000 litres capacity, the company said.
The proposed plant, to come up a on 10 acre land parcel in Ramky Pharma City in Vizag, is expected to be completed in two years time, said Manni Kantipudi, chief executive officer of GVK Biosciences said.
Earlier this year, GVK Biosciences set up formulation plant in Bangalore.
Kantipudi, without disclosing revenue and profit figures, said GVK Biosciences registered topline growth of 40% in the quarter ended 31 December, with a much better percentage of profits.
GVK earns about 50% of its revenue through drug discovery research services, while the remaining comes from contract manufacturing, informatics and clinical research.
Kantipudi said the clinical research business that contributes 11% revenues was hit by government’s new guidelines on clinical trials and legal issues.
“There is lack of regulatory clarity on clinical trials, and government is not giving approvals for fresh clinical trial programmes,” Kantipudi said.
US FDA EXTENDS
LICENSE OF THE GVK BIO BIOMARKER DATABASE
Hyderabad, India: GVK Biosciences (GVK BIO) today announced that it is extending its Clinical Biomarker Database (GOBIOM) license to the Biomarker Qualification Group of the US Food and Drug Administration (USFDA). The GOBIOM database, which has the latest and recently updated information on all the biomarkers reported in various clinical and preclinical studies, will be beneficial to the USFDA in its Biomarker Qualification Process.
The GOBIOM database is a comprehensive compilation of all the clinically evaluated, exploratory and preclinical biomarkers associated with different therapeutic areas reported in global clinical trials, clinical and preclinical studies. GOBIOM contains information on 20,000 biomarkers comprising of biochemical, genomic, imaging, metabolite, cellular and physiological markers, along with multiple data points comprising of experimental, analytical, clinical and statistical data with their qualifications under different medical interventions.
Sreeni Devidas, Vice President, Sales and Marketing, Informatics said “The collaboration with the USFDA has helped GVK BIO in developing the safety biomarker content in GOBIOM. The interconnectivity between organ toxicities to the drug, dose and population was developed with equal emphasis on its preclinical qualification. Biomarker analysis tools were integrated into the database in a manner that has facilitated the user to make a comparative analysis between the biomarkers of their interest. We look forward to continue working and collaborating with the FDA with a view to enhancing the utility of the product further.”
About GVK BIO
GVK Biosciences (GVK BIO) is Asia’s leading discovery, research and development organization providing a broad spectrum of services, stand-alone and integrated, across the R&D value chain. Our discovery services consist of Chemistry, Biology and Informatics; the development services include Clinical Research, Clinical Pharmacology and Process R&D. GVK BIO’s diverse portfolio and global clientele comprising more than 200 customers includes some of the global leading organizations in the fields of pharmaceuticals, biotechnology, agro, life-sciences as well as prestigious academic institutions.
GVK BIO AND ARAGEN
BIOSCIENCE SIGN DEFINITIVE AGREEMENT TO ACQUIRE ARAGEN BIOSCIENCE, INC.
The acquisition of Aragen Bioscience provides GVK BIO with world-class expertise in large molecule R&D services and a unique and extensive set of high-content biological services. Combined with GVK BIO’s established small molecule discovery and development capabilities, this expansion uniquely position GVK BIO as a leading provider of integrated R&D services across both large and small molecule platforms and provides a base for further expansion.
Hyderabad, India and Morgan Hill, CA, USA, January 29th 2014: – Asia’s leading small-molecule contract research organization (CRO), GVK BIO, and Aragen Bioscience, Inc., a privately held US based, pre-clinical CRO specializing in high-value biologics services, announce an agreement through which GVK BIO will acquire the capital stock of Aragen Bioscience. GVK BIO has established itself as a pre-eminent small molecule service provider. This deal enables GVK BIO to expand its service offering to a broader base of organizations and gives GVK BIO expertise in biologics services and a significant US presence. The acquisition provides Aragen with the ability to expand its service offerings, access to GVK BIO’s global sales force and access to new markets.
“As an increasing number of biotech and pharmaceutical companies focus on protein based therapeutics and bio-similars, the acquisition of Aragen Bioscience will strategically enhance GVK BIO’s ability to offer high quality R&D services to the industry from a seamless integrated platform”, said Mr. D. S. Brar, Chairman, GVK BIO.
“Aragen’s scientific excellence and expertise in large-molecule R&D services combined with GVK BIO’s scale, resources, and global reach will create significant synergies for both companies” stated Rick Srigley, President and CEO, Aragen Bioscience.
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No exist to suggest that subject is or was
the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction registered
against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling shareholders,
director, officer or employee of the company is a government official or a
family member or close business associate of a Government official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on Corporate
Governance to identify management and governance. These factors often have been
predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs. |
|
|
1 |
Rs. |
|
Euro |
1 |
Rs. |
INFORMATION DETAILS
|
Information
Gathered by : |
|
|
|
|
|
Analysis Done by
: |
|
|
|
|
|
Report Prepared
by : |
NTH |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
7 |
|
PAID-UP CAPITAL |
1~10 |
7 |
|
OPERATING SCALE |
1~10 |
7 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
8 |
|
--PROFITABILIRY |
1~10 |
7 |
|
--LIQUIDITY |
1~10 |
7 |
|
--LEVERAGE |
1~10 |
7 |
|
--RESERVES |
1~10 |
8 |
|
--CREDIT LINES |
1~10 |
7 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
YES |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
YES |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
DEFAULTER |
|
|
|
--RBI |
YES/NO |
NO |
|
--EPF |
YES/NO |
NO |
|
TOTAL |
|
65 |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment record
(10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.